Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference
Silexion Therapeutics has completed an expanded development plan for SIL204, its next-generation siRNA candidate targeting KRAS-driven cancers. The plan will be presented at the NeauxCancer 2025 Conference in New Orleans from March 27th-29th, 2025.
The strategic plan, building on recent promising preclinical data, aims to maximize SIL-204's potential across multiple delivery approaches. The company's presentation is scheduled for March 28th at 1:00pm during the conference's Innovation track, where they will present their strategic vision alongside recently reported preclinical findings.
The clinical-stage biotechnology company, specializing in RNA interference (RNAi) therapies, will focus particularly on pancreatic cancer in their comprehensive approach to targeting KRAS-driven cancers.
Silexion Therapeutics ha completato un piano di sviluppo ampliato per SIL204, il suo candidato siRNA di nuova generazione che mira ai tumori guidati da KRAS. Il piano sarà presentato al NeauxCancer 2025 Conference a New Orleans dal 27 al 29 marzo 2025.
Il piano strategico, basato su recenti dati preclinici promettenti, mira a massimizzare il potenziale di SIL-204 attraverso molteplici approcci di somministrazione. La presentazione dell'azienda è programmata per il 28 marzo alle 13:00 durante il track Innovazione della conferenza, dove presenteranno la loro visione strategica insieme ai risultati preclinici recentemente riportati.
La compagnia biotecnologica in fase clinica, specializzata in terapie di interferenza dell'RNA (RNAi), si concentrerà in particolare sul cancro pancreatico nel loro approccio globale per affrontare i tumori guidati da KRAS.
Silexion Therapeutics ha completado un plan de desarrollo ampliado para SIL204, su candidato de siRNA de nueva generación dirigido a cánceres impulsados por KRAS. El plan se presentará en la NeauxCancer 2025 Conference en Nueva Orleans del 27 al 29 de marzo de 2025.
El plan estratégico, que se basa en recientes datos preclínicos prometedores, tiene como objetivo maximizar el potencial de SIL-204 a través de múltiples enfoques de administración. La presentación de la empresa está programada para el 28 de marzo a la 1:00 p.m. durante la pista de Innovación de la conferencia, donde presentarán su visión estratégica junto con los hallazgos preclínicos recientemente reportados.
La compañía biotecnológica en etapa clínica, especializada en terapias de interferencia de ARN (RNAi), se enfocará particularmente en el cáncer de páncreas en su enfoque integral para abordar los cánceres impulsados por KRAS.
Silexion Therapeutics는 KRAS에 의해 유도되는 암을 겨냥한 차세대 siRNA 후보물질인 SIL204의 확대 개발 계획을 완료했습니다. 이 계획은 2025년 3월 27일부터 29일까지 뉴올리언스에서 열리는 NeauxCancer 2025 Conference에서 발표될 예정입니다.
최근의 유망한 전임상 데이터를 바탕으로 한 이 전략적 계획은 SIL-204의 잠재력을 여러 전달 접근 방식을 통해 극대화하는 것을 목표로 합니다. 회사의 발표는 3월 28일 오후 1시에 회의의 혁신 트랙에서 예정되어 있으며, 그들은 최근 보고된 전임상 결과와 함께 전략적 비전을 발표할 것입니다.
RNA 간섭(RNAi) 치료에 전문화된 임상 단계 생명공학 회사는 KRAS에 의해 유도되는 암을 겨냥한 포괄적인 접근 방식에서 특히 췌장암에 집중할 것입니다.
Silexion Therapeutics a complété un plan de développement élargi pour SIL204, son candidat siRNA de nouvelle génération ciblant les cancers liés à KRAS. Le plan sera présenté lors de la NeauxCancer 2025 Conference à La Nouvelle-Orléans du 27 au 29 mars 2025.
Le plan stratégique, s'appuyant sur des données précliniques prometteuses récentes, vise à maximiser le potentiel de SIL-204 à travers plusieurs approches de délivrance. La présentation de l'entreprise est prévue pour le 28 mars à 13h00 lors de la piste Innovation de la conférence, où ils présenteront leur vision stratégique ainsi que des résultats précliniques récemment rapportés.
L'entreprise biopharmaceutique en phase clinique, spécialisée dans les thérapies d'interférence de l'ARN (RNAi), se concentrera particulièrement sur le cancer du pancréas dans son approche globale pour cibler les cancers liés à KRAS.
Silexion Therapeutics hat einen erweiterten Entwicklungsplan für SIL204, seinen Next-Generation siRNA-Kandidaten zur Bekämpfung von KRAS-gesteuerten Krebsarten, abgeschlossen. Der Plan wird auf der NeauxCancer 2025 Conference in New Orleans vom 27. bis 29. März 2025 präsentiert.
Der strategische Plan, der auf vielversprechenden aktuellen präklinischen Daten basiert, zielt darauf ab, das Potenzial von SIL-204 über verschiedene Verabreichungsansätze zu maximieren. Die Präsentation des Unternehmens ist für den 28. März um 13:00 Uhr während des Innovationstracks der Konferenz angesetzt, wo sie ihre strategische Vision zusammen mit kürzlich berichteten präklinischen Ergebnissen vorstellen werden.
Das biopharmazeutische Unternehmen in klinischer Phase, das sich auf RNA-Interferenz (RNAi)-Therapien spezialisiert hat, wird sich besonders auf Bauchspeicheldrüsenkrebs in ihrem umfassenden Ansatz zur Bekämpfung von KRAS-gesteuerten Krebsarten konzentrieren.
- Recent preclinical data shows promising results for SIL204
- SIL204 is still in preclinical stage, indicating a long path to potential commercialization
Silexion Therapeutics to Present Innovative New Expanded Development Plan for SIL204 at the Industry Leading 2025 NeauxCancer Conference, Following Recently Reported Groundbreaking Preclinical data from Orthotopic Models; Further Details about the Plan to be Reported Shortly Alongside the Presentation
Grand Cayman, Cayman Islands, March 21, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced it has completed an expanded development plan for its next-generation siRNA candidate, SIL204, which the company’s management will be presenting at the upcoming Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer 2025 Conference being held March 27th-29th, 2025 at The Roosevelt New Orleans Hotel in New Orleans, LA.
The newly completed strategic plan builds upon Silexion's recent promising preclinical data and is designed to maximize SIL-204's potential across multiple delivery approaches to address the challenges of KRAS-driven cancers. The Company plans to report further details on the expanded plan alongside its presentation at the conference.
A company presentation will take place during the conference's Innovation track on Friday, March 28th at 1:00pm. During this session, Silexion will present its strategic vision alongside recently reported preclinical findings from its SIL-204 program.
"We look forward to sharing our expanded development plan for SIL-204 at the upcoming NeauxCancer Conference," said Ilan Hadar, Chairman and CEO of Silexion Therapeutics. "Recent advances in our preclinical program have informed a more comprehensive approach to targeting KRAS-driven cancers, particularly pancreatic cancer. Our presentation will outline how we plan to leverage these findings to advance SIL-204 toward clinical development."
Silexion's management team will be available for one-on-one meetings during the conference. Interested investors should contact Silexion's investor relations representatives as listed below.
About Silexion Therapeutics
Silexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers. The company's first-generation product, LODER™, has shown promising results in a Phase 2 clinical trial for non-resectable pancreatic cancer. Silexion is also advancing its next-generation siRNA candidate, SIL204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies. The company remains committed to pushing the boundaries of therapeutic innovation in oncology, with a focus on improving outcomes for patients with difficult-to-treat cancers. For more information please visit: https://silexion.com
Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this communication, including statements regarding Silexion’s business strategy and ongoing studies are forward-looking statements. These forward-looking statements are generally identified by terminology such as "may", "should", "could", "might", "plan", "possible", "project", "strive", "budget", "forecast", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not limited to: (i) Silexion’s ability to successfully complete preclinical studies and initiate clinical trials; (ii) Silexion’s strategy, future operations, financial position, projected costs, prospects, and plans; (iii) the impact of the regulatory environment and compliance complexities; (iv) expectations regarding future partnerships or other relationships with third parties; (v) Silexion’s future capital requirements and sources and uses of cash, including its ability to obtain additional capital; and (vi) other risks and uncertainties set forth in the documents filed or to be filed with the SEC by the company, including the Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 18, 2025. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law.
Company Contact
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
mirit@silexion.com
Investor Contacts
Chuck Padala
Lifesci Advisors
Chuck@lifesciadvisors.com
Arx | Capital Markets Advisors
North American Equities Desk
silexion@arxadvisory.com
FAQ
What is the expanded development plan for Silexion's (SLXN) SIL204 drug candidate?
When will Silexion (SLXN) present its SIL204 development plan?
What type of cancer does Silexion's (SLXN) SIL204 target?
What technology does Silexion (SLXN) use in SIL204?
